IOBTQ (IO Biotech) Buyback Yield %: 0.00 (As of Jun. 28, 2026)


What is IO Biotech Buyback Yield %?

IO Biotech IOBTQ +27.50% Buyback Yield % is 0.00 as of Jun. 28, 2026. The stock has 1 warning sign investors should review. Among 743 Biotechnology companies, IO Biotech ranks worse than 134589.37% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

IO Biotech's current buyback yield was 0.00%.

IO Biotech Buyback Yield % Historical Data

* Premium members only.

The historical data trend for IO Biotech's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IO Biotech Buyback Yield % Chart

IO Biotech Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Buyback Yield %
Get a 7-Day Free Trial 0.00 -62.42 0.00 -60.60 0.00

IO Biotech Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

IOBTQ vs CNBX, ENDV, RGBP: Buyback Yield % Comparison

For the Biotechnology subindustry, IO Biotech's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IO Biotech Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IO Biotech's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where IO Biotech's Buyback Yield % falls into.


IO Biotech Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

IO Biotech's Buyback Yield for the fiscal year that ended in Dec. 2024 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 60.61052
=0.00%

IO Biotech's annualized Buyback Yield for the quarter that ended in Sep. 2025 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0) / 25.3051652
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of 0.00 mean?
IO Biotech (IOBTQ) has a Buyback Yield % of 0.00 as of Jun. 28, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on IO Biotech and its competitors. According to the industry distribution chart, IO Biotech ranks #999999 out of 743 companies in the Biotechnology industry.
Is IO Biotech's Buyback Yield % too high?
IO Biotech's current Buyback Yield % is 0.00. Based on the distribution chart, IO Biotech ranks #999999 out of 743 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does IO Biotech's Buyback Yield % compare to CNBX and ENDV?
According to the Biotechnology industry distribution chart, IO Biotech ranks #999999 out of 743 companies for Buyback Yield %. This places IO Biotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on IO Biotech and its competitors. IO Biotech's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IO Biotech stock overvalued right now?
IO Biotech (IOBTQ) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For IO Biotech (IOBTQ), the current Buyback Yield % is 0.00 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

IO Biotech Business Description

Address Ole Maaloes Vej 3, Copenhagen N, DNK, DK-2200
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.